4-Aminopyridine to Treat Skin Burns

Part of paid clinical trials in Tucson, Arizona.

Sponsor
John Elfar
Study ID
NCT06596434
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Burns
  • Second Degree Burn
  • Wounds and Injuries

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Drug: 4-Aminopyridine — DRUG
    Active study drug
  • Placebo — OTHER
    Placebo comparator

Study Details

Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The investigational treatment will be used to test the hypothesis that 4-AP accelerates burn healing in traumatically burned patients.

Key Dates

Start date
Jan 1, 2026
Status verified
Mar 2026
Primary completion
Jun 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group A: 4-aminopyridine
    Dalfampridine (generic) 10 mg capsule PO every 12 hours
  • Placebo Comparator: Group B: Placebo
    Placebo - 1 capsule PO every 12 hours

Primary Outcome Measure

Healing rate [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of ArizonaTucsonArizona85724
Carly J Deal
[email protected]
520-626-1588
Veronica Rangel, BS
[email protected]
5206164024

Find similar trials in Tucson, AZ

By research site
University of Arizona· Tucson, AZ

Related Studies